Medroxyprogesterone Acetate Plus Metformin to Prevent Persistent Endometrial Hyperplasia

Authors

  • Vakkas Korkmaz Dr. Sami Ulus Maternity and Women’s Health Training and Research Hospital, Department of Obstetrics and Gynecology, Ankara
  • Enis Özkaya Dr. Sami Ulus Maternity and Women’s Health Training and Research Hospital, Department of Obstetrics and Gynecology, Ankara
  • Tuncay Küçüközkan Dr. Sami Ulus Maternity and Women’s Health Training and Research Hospital, Department of Obstetrics and Gynecology, Ankara
  • Fadıl Kara Dr. Sami Ulus Maternity and Women’s Health Training and Research Hospital, Department of Obstetrics and Gynecology, Ankara
  • Yasemin Çekmez Dr. Sami Ulus Maternity and Women’s Health Training and Research Hospital, Department of Obstetrics and Gynecology, Ankara
  • Hilal Korkmaz Keçioren Training and Research Hospital, Department of Emergency Medicine, Ankara

Keywords:

Medroxyprogesterone acetate, Metformin, Endometrial hyperplasia

Abstract

OBJECTIVE: To determine the effect of metformin on treatment response in simple endometrial hyperplasia without atypia.
STUDY DESIGN: In this study, we identified 134 women with simple endometrial hyperplasia without atypia. Seventy two of these women were administered cylic oral medroxyprogesterone acetate 10 mg/day for 3 months, 62 of these women were also receiving metformin 1000 mg/day due to preexisting insulin resistance and and all subjects underwent control endometrial sampling after treatment. All subjects were evaluated in terms of age, gravidity, parity, body mass index (BMI), menstrual cycle, luteal phase endometrial thickness, uterine fibroids, ovarian cysts, serum CA 125 levels, systemic disorders, cigarette smoking. All parameters and metformin were assessed for the effects on treatment success.
RESULTS: Out of 72 women who were administered medroxyprogesterone acetate 10 mg/day for 3 months, 15 of them were diagnosed as endometrial hyperplasia in control endometrial sampling while only 5 women had persistent endometrial hyperplasia in group with receiving both medroxyprogesterone acetate 10 mg/day and metformin 1000 mg/day (P<0.05). Age, gravidity, serum CA125, BMI, pretreatment endometrial thickness were comparable between groups (P>0.05).
CONCLUSION: Medroxyprogesterone acetate and metformin may be used as an adjunctive therapy for persistent endometrial hyperplasias especially in women with high body mass index.

Downloads

Download data is not yet available.

Downloads

Published

2013-08-29

How to Cite

1.
Korkmaz V, Özkaya E, Küçüközkan T, Kara F, Çekmez Y, Korkmaz H. Medroxyprogesterone Acetate Plus Metformin to Prevent Persistent Endometrial Hyperplasia. Gynecol Obstet Reprod Med [Internet]. 2013Aug.29 [cited 2024Dec.22];19(2):96-9. Available from: https://gorm.com.tr/index.php/GORM/article/view/194

Issue

Vol. 19 No. 2 (2013)

Section

Gynecology and Gynecological Oncology

License

Copyright (c) 2013 Vakkas Korkmaz, Enis Özkaya, Tuncay Küçüközkan, Fadıl Kara, Yasemin Çekmez, Hilal Korkmaz

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

CC BY

All the articles published in GORM are licensed with "Creative Commons Attribution 4.0 License (CC BY 4.0)". This license entitles all parties to copy, share and redistribute all the articles, data sets, figures and supplementary files published in this journal in data mining, search engines, web sites, blogs and other digital platforms under the condition of providing references.